VENLO, the Netherlands, November 6, 2017 /PRNewswire/ --
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the third quarter and first nine months of 2017, delivering on goals for improvements in adjusted net sales and adjusted earnings.
Click here for the full press release
Contacts Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 +1-240-686-2222 Dr. Sarah Fakih Associate Director Investor Relations +49-2103-29-11457 Email: firstname.lastname@example.org ir.qiagen. com
Public Relations: Dr. Thomas Theuringer Senior Director Public Relations and Digital Communications +49-2103-29-11826 +1-240-686-7425 Email: email@example.com pr.qiagen.com
Download the QIAGEN Investor Relations App
SOURCE QIAGEN N.V.
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All